A prospective audit of complications in 100 consecutive pediatric percutaneous renal biopsies done under real-time ultrasound guidance

R. Sinha1,2, B. Maji1, B. Sarkar2, S. Meur3

1Division of Paediatric Nephrology, Institute of Child Health, 2Division of Paediatric Nephrology and 3Paediatric Intensive Care, Vision Care Hospital (AMRI Hospitals), Kolkata, West Bengal, India

ABSTRACT

Despite being a common procedure, percutaneous renal biopsy (PRB) carries the potential for complications. The British Association of Paediatric Nephrologist (BAPN) has published standards for pediatric PRB. As Indian data are scarce, we conducted a prospective audit of 100 consecutive pediatric renal biopsies (60% males) under real-time ultrasound guidance. Nephrotic syndrome was the most common indication for PRB (68%) with minimal change disease (30%) and focal segmental glomerulosclerosis (25%) being the most common histopathological lesions. Gross hematuria was observed in six cases. Major complications was noted in one case, who needed longer hospital stay. The result of the audit demonstrated achievability of BAPN standards. In addition, we also show the usefulness of 16 gauge biopsy needle over 18 gauge biopsy needles (median number of glomeruli 25, range 3–90 vs 13, range 6–46, \( P = 0.001 \)) without any increase in complications. Being a single center study, we do hope that our results will encourage a wider survey on the current state of pediatric PRB.

Key words: Audit, biopsies, complications, pediatric, renal

Introduction

Introduction of safe renal biopsy has been hailed as one of the important paradigm shift in nephrology and contributed significantly to the establishment of nephrology as a separate discipline.[1] Iversen and Brun get the credit for publishing the first series of percutaneous renal biopsy (PRB) in 1951, which was done in sitting position and, thereafter, Kark and Muehrcke published their experience in 1954 using prone position, the current standard procedure.[2,3] Since then, there has been steady improvement in the technique of PRB including real-time ultrasound (USG) guidance and automated biopsy needles. Despite this, it still carries significant potentials for complications, partly due to lack of standardization of practice.[4,5] Keeping this in mind, The British Association for Paediatric Nephrology (BAPN) published a minimal standard guideline for assessing the performance of pediatric PRB.[6] Indian data are either retrospective or have small sample size.[7-9] One of the ways quality can be assessed is through clinical audit, and comparison against a set standard.[10] In this manuscript, we report prospective audit of 100 consecutive pediatric PRB assessed against BAPN criteria.[6] To the best of our knowledge, this is the largest such prospective data series from India.

How to cite this article: Sinha R, Maji B, Sarkar B, Meur S. A prospective audit of complications in 100 consecutive pediatric percutaneous renal biopsies done under real-time ultrasound guidance. Indian J Nephrol 2016;26:329-34.
Materials and Methods

A prospective audit of 100 consecutive pediatric renal biopsies was undertaken at the Vision Care Hospital, AMRI, Kolkata between July 2012 and September 2014. All biopsies were done after admission. Verbal information about the procedure and its complications were given to all parents, and a standardized informed written consent obtained prior to the procedure. Standard investigations included complete hemogram, coagulation profile, viral (hepatitis B, hepatitis C, and human immunodeficiency virus) serology and blood group testing. Abnormal hemostasis, uncontrolled hypertension, and active urinary tract infection were ruled. In the presence of coagulation abnormalities, results were repeated after Vitamin K injection, and if still abnormal, biopsies were done under the cover of fresh frozen plasma. No biopsies were undertaken in the presence of disseminated intravascular coagulopathy or active bleeding. Children were temporarily shifted to Pediatric Intensive Care Unit, and biopsies done at the bedside in the presence of persons skilled in pediatric advanced life support.

The procedure was done under deep sedation with intravenous midazolam and ketamine. Children with blood pressure ≥90th centile for age and sex were given a combination of fentanyl and propofol to prevent worsening hypertension through catecholaminergic effects of ketamine. Heart rate, blood pressure, electrocardiography, respiratory rate, and oxygen saturation were monitored during the procedure and until full recovery from anesthetics. Supplemental oxygen was given as necessary. Equipment and drugs for resuscitation and emergency airway support including intubation were kept ready for all children.

All renal biopsies were performed under real-time USG guidance wherein both visualization of kidney and biopsy [Figure 1] were done by a single operator. Native biopsies were done in a prone position and transplant in supine. In cases of native biopsies, the lower pole of the left kidney was targeted with automated biopsy needle (Bard®). Two cores were attempted for light microscopy and immunofluorescence whereas an additional core was taken if electron microscopy was deemed necessary. USG was done immediately post PRB to identify any peri-renal hematoma.

Post biopsy vitals were monitored every 15 min for the 1st h, every 30 min for next hour, hourly for next 2 h, 2 hourly for another 2 h, and thereafter 4 hourly. Urine was collected, and the sample stored in the separate container to monitor gross hematuria if any. If the child was hemodynamically stable s/he was transferred to the pediatric ward after 6 h, and discharged the next day if stable. In the presence of gross hematuria or significant hemodynamic instability, a repeat USG with Doppler was done within 24 h. Paracetamol was given round the clock (4 hourly) for 48 h. If pain was not controlled

Figure 1: Real time ultrasound-guided percutaneous renal biopsy by a single operator

| Table 1: Comparison of Indian data on paediatric renal biopsies |
|---------------------------------------------------------------|
| **Relevant Indian studies** | **Nammalwar et al.**[7] | **Mahajan et al.**[8] | **Chopra et al.**[9] | **Current study** |
|--------------------------|-----------------------|---------------------|-------------------|------------------|
| **Type of study**        | Retrospective         | Retrospective       | Prospective       | Prospective      |
| **Number of children**   | 250                   | 67                  | 57                | 100              |
| **Minor complication**   | 49.6                  | 44%                 | Not mentioned     | 5%               |
| **Major complications**  | 6%                    | 12%                 | 3.5%              | 1%               |
| 1 renal loss             |                       | Gross hematuria=3   |                   | 1 child required |
|                         |                       | Perinephric hematoma=5|                  | prolongation of stay |
|                         |                       | Life-threatening episode=2|                 |                  |
| **Failed biopsy**        | 4.8% (<5 glomeruli)  | 4% (<5 glomeruli)  | None              | None             |
|                         |                       | 3.5% (<10 glomeruli)|                   | 2% (<5 glomeruli)|

NB: (a) Definition of minor complication-Nammalwar et al.[7] Mild macroscopic hematuria, gross hematuria lasting for maximum of 48-72 h and resolving on its own without an appreciable drop in hemoglobin or requiring blood transfusion, Mahajan et al.[8] Microscopic hematuria, Chopra et al.[9] Not mentioned, Current study: Gross hematuria not requiring interventions or extension of monitoring/stay. (b) Definition of major complication-Nammalwar et al.[7] Subcapsular hematoma or injury to other internal viscera, biopsy site infection, Mahajan et al.[8] Gross hematuria, perinephric hematoma, blood transfusion, biopsy site infection, organ loss, AVFs hemodynamic instability, death, Chopra et al.[9] All gross hematuria, Current study: Gross hematuria requiring interventions or extension of monitoring/stay, perinephric hematoma greater than 2 cm, organ injury, biopsy site infection, hemodynamic instability, death.(c) Adequacy-Nammalwar et al.[7] Number of glomeruli <5, Mahajan et al.[8] Number of glomeruli <5, Chopra et al.[9] Histopathologist being able to give a diagnosis, Current study: Histopathologist being able to give a diagnosis. AVFs: Arterio-venous fistulas

Sinha, et al.: Prospective audit of paediatric renal biopsies

Sep 2016 / Vol 26 / Issue 5

Indian Journal of Nephrology
adequately with this, codeine was prescribed as an additional analgesic.

An audit proforma was used wherein demographic details, indications for biopsy, biochemical (creatinine, albumin)/hematological (blood count and coagulation profile)/serological parameters, type of sedation, number of attempts (passes), number of cores, biopsy needle size, and any complications post renal biopsy were noted. Final audit was done against the BAPN audit criteria [Table 2].

Descriptive statistics was used to define baseline variables. Test for significance was done by Chi-square for nominal data and ANOVA for parametric/nonparametric data. \( P < 0.05 \) was considered as significant. Statistical analysis was performed using Smith’s Statistical Package (SSPVersion 2.80, September 26, 2011, Manufacturer Gary Smith, UK).

### Results

Demographic analysis of our 100 cases showed a male preponderance (60%) with a median age of 8 years (range: 0.3–17 years). Ketamine and midazolam were used for sedation for 62% of children and propofol and fentanyl for the rest. There was no sedation related complications.

The clinical indications for biopsy for native kidneys (n = 98) are shown in Table 3 and the final histopathological diagnosis in Table 4. The criteria for biopsy of transplant kidneys (n = 2) was at least 10% rise in plasma creatinine from baseline or other clinical indication of possible rejections or recurrence. The indications for biopsy in native kidney steroid resistant nephrotic syndrome (NS) i.e., SRNS = 39%, steroid dependent nephrotic syndrome prior to starting calcineurin inhibitor or rituximab = 17%, and atypical/late onset NS = 12%. The most common histopathological diagnoses were minimal change NS (30%), focal segmental glomerulosclerosis (25%), systemic lupus erythematosus nephritis (10%), and IgM nephropathy (10%).

The biopsy was done by 16 gauge needles in 71% cases and 18 gauge needles in 28% cases. One 3 months old had a biopsy with 20 gauge needle. Two passes gave adequate kidney tissue in 72% of cases whereas another 25% children required total 3 passes. The median pass/attempt to core ratio was 1 (range 1–2). Histopathologist found the tissue to be satisfactory for 100% samples for light microscopy and in 99% samples for immunofluorescence. The median number of glomeruli per biopsy was 22 (range 3–76). In 56% cases, the specimen had ≥20 glomeruli, and 22% had 10–19 glomeruli. Only 2 children had less than five glomeruli. About 6% of the children had gross hematuria. Apart from one, all resolved within 8 h, and none required blood transfusion or any intervention. Immediate post renal biopsy USG did not reveal any significant hematoma (>2 cm).

### Table 2: BAPN standards and its comparison with current study

| BAPN standards for renal biopsy | Current audit results |
|--------------------------------|-----------------------|
| 1. All patients should receive appropriate written information about the biopsy procedure | 1. Verbal information about the procedure and its complications were given to all parents, and written consent was taken |
| 2. For both native and transplant biopsies, ≤3 passes should be achieved in 80% of occasions | 2. ≤3 passes were obtained in 97% cases |
| 3. There should be adequate tissue (defined as-histopathologist being able to reach to diagnosis) for diagnosis on 95% of occasions | 3. Adequate tissue for histopathological diagnosis was obtained in 100% cases. Only one sample was found to be inadequate for immunofluorescent study |
| 4. Major complication (defined as delay in patient discharge as a result of postbiopsy complications or requirements for further investigations, interventions or monitoring as a result of a biopsy) should be <5% | 4. Only one child (1%) suffered major complication in terms of persistent macroscopic hematuria requiring hospital admission for more than 24 h |

BPAN: British Association of Paediatric Nephrologist

### Table 3: Indication for biopsies in native kidney

| Indication | Percentage |
|------------|------------|
| SLE | 8 |
| SRNS | 39 |
| Atypical/late onset NS | 12 |
| SDNS | 17 |
| Acute renal failure | 7 |
| Others | 5 |
| Acute glomerulonephritis | 4 |
| Posttransplant | 2 |
| Chronic kidney disease | 3 |
| HSP | 3 |
| Total | 100 |

SLE: Systemic lupus erythematosus, NS: Nephrotic syndrome, SRNS: Steroid resistant nephrotic syndrome, SDNS: Steroid dependent nephrotic syndrome, HSP: Henoch-Schönlein purpura

### Table 4: Final histopathological diagnosis

| Diagnosis | Percentage |
|-----------|------------|
| IgM nephropathy | 10 |
| MCNS | 30 |
| FSGS | 25 |
| Posttransplant (normal histopathology) | 2 |
| HSP/IgA nephropathy | 6 |
| SLE Nephritis | 10 |
| MPGN | 6 |
| Others | 11 |
| Total | 100 |

MCNS: Minimal change nephrotic syndrome, FSGS: Focal segmental glomerulosclerosis, MPGN: Membranoproliferative glomerulonephritis, HSP: Henoch-Schönlein purpura, SLE: Systemic lupus erythematosus
median number of glomeruli obtained from biopsy with
16 gauge (median 25, range 3–90) was significantly
greater than those obtained by 18 gauge needle (median
13, range 6–46), \( P = 0.001 \). Gross hematuria happened
was numerically more frequent with 18 than 16 gauge
needle (\( n = 2, 7.1\% \) vs \( n = 4, 5.6\% \)). Gross hematuria
correlated with attempts to core ratio (1.5 \( \pm \) 0.44 vs.
1.1 \( \pm \) 0.26, \( P = 0.002 \)). We did not find any correlation
between gross hematuria and sex or age. The audit result
as per BAPN criteria is shown in Table 2.

Discussion

Kidney being a highly vascular organ, PRB (although
a relatively safe procedure) does have the potential of
resulting in complications.\(^{13}\) Hence, although the likelihood
of getting an adequate tissue is as high as 99–100%,\(^ {9,14} \) its
success is not measured only by the adequacy of the biopsy
tissue but also by the safety of the procedure. Biopsy is more
challenging in children because of various factors including
wide range of size, variable level of patient cooperation,
and variable degree of analgesia/anesthesia requirement.\(^ {4} \)
Despite being a common procedure in pediatric nephrology,
recent surveys have shown lack of uniformity of practice
even in developed countries and data from India remains
scanty.\(^ {6,7,9} \) In this current largest prospective audit on
pediatric PRB from India performed under real-time USG
guidance by a pediatric nephrologist, we have demonstrated
its overall efficacy as well as safety to be at par with BAPN
standards.

All our biopsies were done with full resuscitation per
the European Society of Paediatric Radiology (ESPR)
guidelines.\(^ {15} \) USG guidance was used because of advantages
such as continuous visualization of both kidney and needle,
avoiding exposure to radiation, permitting procedure to
be performed at bedside and avoiding administration of
nephrotoxic contrast media.\(^ {16} \) Recent studies have
demonstrated the advantage of real time USG guidance,\(^ {17} \)
as well as safety and efficacy of nephrologist, performed USG
guided PRB over radiologist performed PRB.\(^ {18} \)

Similar to previous Indian studies,\(^ {7,9} \) various forms
of NS were the most common indications for the
biopsies [Table 3]. In contrast to the BAPN survey\(^ {4} \) where
in Henoch Schonlein Purpura nephritis was the most
common final histopathological diagnosis, we found both
minimal change nephrotic syndrome and focal segmental
glomerulosclerosis [Table 4] to be more common probably
reflecting the known higher incidence of NS among the
Asian population.\(^ {19,20} \)

Unlike the studies by either Mahajan et al.\(^ {8} \) or Chopra
et al.,\(^ {9} \) most of the biopsies were performed with 16
gauge needles (71%). Whereas this is in contrast to the
ESPR recommendation,\(^ {15} \) this reflects the general trend
among the nephrologist to use bigger needles.\(^ {11,21,22} \) Similar to the large Norwegian registry analysis, we
found that 16 gauge needles yielded statistically greater
numbers of glomeruli with a non significant trend of
higher complications.\(^ {23} \) This apparently paradoxical
increase in complications has been postulated to be due to
the tendency of thinner needles to deviate from the
lower pole to proximal direction (where vessel density is
higher), with subsequent bleeding into the pelvis.\(^ {23} \) Only
a single previous Indian study\(^ {9} \) documented average
yield and compared to that our yield of glomeruli (median
22 vs. 17) was higher. We recorded \( \leq 2 \) attempt/pass in
72% cases whereas the Norwegian study\(^ {23} \) reported
adequate biopsy material from 85%. We postulate that
our slightly lower percentage might be due to the absence
of dissecting microscope in our procedure room wherein
we were often forced to take an additional sample to
ensure that we have got adequate number of glomeruli.

The success of PRB should be determined both by the
adequacy of the tissue and the incidence of complications.
Gross or macroscopic hematuria continues to be the
most frequent important complication if it necessitates
blood transfusion, surgical intervention/embolization
or prolonged hospital stay.\(^ {4,23-28} \) In our series, gross
hematuria occurred in 6%, lower than 49.6% observed
by Nammalwar et al.,\(^ {7} \) it was similar to the other
Indian reports.\(^ {8,9} \) Among the pediatric studies from
India, Chopra et al.\(^ {9} \) also reported similar findings,
but in the report from Mahajan et al.,\(^ {8} \) 3% developed
hemodynamic compromise and needed a blood
transfusion. In the Norwegian study of 715 children,\(^ {23} \)
one needed transfusion and another embolization/
surgical intervention. Post-biopsy hematomas\(^ {26} \)
greater than 2 cm is likely to have clinical significance,\(^ {29} \)
and we did not document any such. Nammalwar et al.\(^ {7} \)
documented subcapsular hematoma in 6% cases, Mahajan
et al.\(^ {8} \) in 7% and Chopra et al.\(^ {9} \) in none, whereas the
Norwegian study reported an incidence of 8.1%.\(^ {22} \) In
contrast, there are studies documenting higher incidence
of perirenal hematomas ranging from 30% to 90%.\(^ {26,30} \)
This discrepancy is likely to be a reflection of how
extensively they were looked for and as to whether there
were any size limits of hematomas for documentation. AVF
is another potential complication of PRB, which are often
silent. Angiography-based imaging studies have reported
an incidence of about 10% with the majority (over 90%)
resolving spontaneously a year later. Significant AVF
usually presents with hypotension, and although none
of our children experienced significant hypotension,
we did look for AVF among those with gross hemorrhage but
none was found. Among the Indian studies significant
hypotension were noted by both Nammalwar et al. as well as Mahajan et al., but none of them mentioned AVF.\cite{7,8} The Norwegian study reported a single AVF in their series of 9288 biopsies in both adults and children.\cite{21} Catastrophic complications such as renal loss or loss of life was not seen in our study and neither was it reported in either of the recent Indian reports.\cite{6,8,9} Nammalwar et al. did report the loss of a kidney, but it analyzed a period ranging from 1998 to 2002 through which period the procedure had evolved from blind renal biopsy to USG guided.\cite{77} Fortunately, the introduction of USG guidance and the automated biopsy gun has reduced the rate of catastrophic complications to practically nil as evident in more recent publications.\cite{4,8,9,14,23,24} Studies have tried to identify risk factors for post renal biopsy bleeding with variable results. In the prospective assessment by Manno et al.\cite{26} among 471 adult patients, younger age, female sex, and prolonged partial thromboplastin time were found to be significant predictors after adjusting for confounding factors. On the other hand in the Norwegian study,\cite{23} chronic kidney disease stages 3–5 and smaller center size (<30 biopsies/year) were the significant risk factors. Although we did not found any correlation between ages, sex, or creatinine value with the risk of gross hematuria, similar to Ori et al.\cite{25} we did observe a significant link between number of attempts and gross hematuria.

Analyzing our performance as per BAPN criteria [Table 2],\cite{6} we met most of them but also identified certain issues that could be improved.

**All patients should receive appropriate written information about the biopsy procedure**

None of the Indian studies mentioned of providing written information. Even the UK audit\cite{41} found that 6 of the 11 centers did not provide families an information sheet or booklet about the renal biopsy. Although we did discuss the biopsy indication and complications with the parents, we also did not provide any written information (post-audit this is currently under production).

**For both native and transplant biopsies ≤3 passes should be achieved in 80% of occasions**

We were able to achieve this in 97%. Whereas neither Nammalwar et al.\cite{77} nor Suri et al.\cite{8} documented number of passes, Chopra et al.\cite{9} achieved a 100% whereas in BAPN audit\cite{41} 3 out of 11 centers could not achieve this target and scored below 80%.

**There should be adequate tissue for diagnosis on 95% of occasions**

Adequacy has been defined by BAPN as to histopathologist being able to reach a diagnosis based on the sampled tissue. Using this criterion, Chopra et al.\cite{9} reported a 100% success whereas keeping a cut-off of 10 glomeruli they were able to achieve the target in 96.5% cases. In the UK audit,\cite{41} 97.5% of tissue sample were adequate for light microscopy and 80.5% for immunofluorescence. We achieved 100% adequacy for light microscopy and 99% for immunofluorescence, whereas ≥10 glomeruli were obtained in 78% cases.

**Major complication should be <5%**

BAPN defined major complication as delay in patient discharge as a result of postbiopsy complications or requirements for further investigations, interventions, or monitoring as a result of a biopsy. The UK audit\cite{41} found major complications in 10.4% wherein only 3 out of the 11 centers studied achieved the target of <5%. Unlike the original BAPN standard, Chopra et al.\cite{9} defined major complications as all cases of gross hemorrhage and quoted a rate of 3.5% but did state that none required further intervention. Similarly, although we found gross hemorrhage in 6% cases, our major complication rate was only 1% (since only a single child required prolonged monitoring necessitating extension of hospital stay).

Despite the obvious strength of being the first Indian paper to prospectively analyze the outcome of pediatric PRB through a systematic audit in 100 consecutive children, our paper does have some major limitations. Being a single center experience, the results will be difficult to extrapolate to mirror the state in the country. Second, although it is the largest number of pediatric PRB prospectively analyzed from India, it still is a relatively small number, and some of our conclusions are likely to be influenced by this small numbers. These limitations have to be interpreted in the light of the objective of this audit which was exclusive to compare our current practice of PRB with a set standard i.e., BAPN.\cite{6}

**Conclusion**

We demonstrated that BAPN standards\cite{6} in pediatric PRB are achievable even in Indian setup. Simultaneously, we identified some constraints including the need for a proper information leaflet for parents, so that the family and the child can be properly prepared for this process and need for dissecting microscope in the procedure room so that if satisfactory tissue has been obtained further attempts/passes can be avoided. Last, it is envisaged that this audit will lead to a pan-India study of the current state of pediatric PRB because as shown by the UK/French publications,\cite{14,33} there can be wide variations between centers.

**Financial support and sponsorship**

Nil.
Conflicts of interest
There are no conflicts of interest.

References

1. Cameron JS, Hicks J. The introduction of renal biopsy into nephrology from 1901 to 1961: A paradigm of the forming of nephrology by technology. Am J Nephrol 1997;17:347-58.
2. Iversen P, Brun C. Aspiration biopsy of the kidney. Am J Med 1951;11:324-30.
3. Kark RM, Muehrcke RC. Biopsy of kidney in prone position. Lancet 1954;266:1047-9.
4. HUSGain F, Mallik M, Marks SD, Watson AR; British Association of Paediatric Nephrology. Renal biopsies in children: Current practice and audit of outcomes. Nephrol Dial Transplant 2010;25:485-9.
5. Bollée G, Martinez F, Moulin B, Meulders Q, Rougier JP, Ording-Mueller LS, et al. Use of ultrafast ultrasound to improve percutaneous renal biopsy in 295 children and adolescents: Role of ultrasound and analysis of complications. Pediatr Nephrol 2014;29:1301-8.
6. Available from: http://www.renal.org/docs/default-source/renal‑biopsy‑standards‑statement.pdf?sfvrsn=2. [Last accessed 2015 Apr 14].
7. Nammalwar BR, Vijayakumar M, Prahlad N. Experience of renal biopsy in children with nephrotic syndrome. Pediatr Nephrol 2006;21:286-8.
8. Mahajan V, Suri D, Saxena A, Nada R. Should ultrasound guided percutaneous renal biopsy in children be done in a day care setting? Indian J Nephrol 2010;20:21-4.
9. Chopra YR, Saha A, Kapoor K, Bagri N, Dubey NK, Batra VV. Percutaneous renal biopsy in children: Are British association of pediatric nephrology standards achievable? Indian J Nephrol 2014;24:130-1.
10. Benjamin A. Audit: How to do it in practice. BMJ 2008;336:1241-5.
11. Parker RI, Mahan RA, Giugliano D, Parker MM. Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children. Pediatrics 1997;99:427-31.
12. Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology 2005;103:20-4.
13. Korbet SM. Nephrology and the percutaneous renal biopsy: A procedure in jeopardy of being lost along the way. Clin J Am Soc Nephrol 2012;7:1545-7.
14. Franke M, Kramarczyk A, Taylan C, Maintz D, Hoppe B, Koerber F. Ultrasound-guided percutaneous renal biopsy in 295 children and adolescents: Role of ultrasound and analysis of complications. Pediatr Nephrol 2014;29:114737.
15. Riccabona M, Lobo ML, Willu U, Avni F, Damasio B, Ording-Mueller LS, et al. ESPR uroradiology task force and ESUR Paediatric Work Group – Imaging recommendations in paediatric uroradiology, part VI: Childhood renal biopsy and imaging of neonatal and infant genital tract. Minutes from the task force session at the annual ESPR Meeting 2012 in Athens on childhood renal biopsy and imaging neonatal genitalia. Pediatr Radiol 2014;44:496-502.
16. Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002;22:254-67.
17. Maya ID, Maddela P, Barker J, Allon M. Percutaneous renal biopsy: Comparison of blind and real-time ultrasound-guided technique. Semin Dial 2007;20:355-8.
18. Yesudas SS, Georgy NK, Manickam S, Raheena A, Monai RC, Noble BA, et al. Percutaneous real-time ultrasound-guided renal biopsy performed solely by nephrologists: A case series. Indian J Nephrol 2010;20:137-41.
19. Sinha A, Hari P, Sharma PK, Gulati A, Kalaivani M, Mantan M, et al. Disease course in steroid sensitive nephrotic syndrome. Indian Pediatr 2012;49:881-7.
20. Feehally J, Kendall NP, Swift PG, Walls J. High incidence of minimal change nephrotic syndrome in Asians. Arch Dis Child 1985;60:1018-20.
21. Gupta RK, Balogun RA. Native renal biopsies: Complications and glomerular yield between radiologists and nephrologists. J Nephrol 2005;18:553-8.
22. Nicholson ML, Wheatley TJ, Doughman TM, White SA, Morgan JD, Veitch PS, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000;58:390-5.
23. Tendel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012;7:1591-7.
24. HUSGain F, Watson AR, Hayes J, Evans J. Standards for renal biopsies: Comparison of inpatient and day care procedures. Pediatr Nephrol 2003;18:53-6.
25. Oli Y, Neuman H, Chagncac A, Siegal A, Tobar A, Itkin M, et al. Using the automated biopsy gun with real-time ultrasound for native renal biopsy. Isr Med Assoc J 2002;4:698-701.
26. Manno C, Strippoli GF, Arnesano L, Bonifati C, Campobasso N, Gesualdo L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004;66:1570-7.
27. Skalova S, Rejtar P. Safety profile of paediatric percutaneous ultrasoundography-guided renal biopsies. Singapore Med J 2010;51:481-3.
28. Attebarmakan VK, Guthinger WP, Yakub VN, Gutierrez OH, Linke CA. Percutaneous kidney biopsies. Complications and their management. Urology 1981;18:118-22.
29. Ishikawa E, Nomura S, Hamaguchi T, Obe T, Inoue-Kiyohara M, Oosugi K, et al. Ultrasoundography as a predictor of overt bleeding after renal biopsy. Clin Exp Nephrol 2009;13:325-31.
30. Gebel M, Kühn K, Döhring W, Freise J. Ultrasoundography and computed axial tomography in the detection and monitoring of renal hematomas following ultrasonically guided percutaneous renal biopsy. Ann Radiol 1985;29:25-7.